flow trial semaglutide kidney outcomes 2024 nejm hazard ratio 🔴Cardiovascular with by severity of chronic disease in type 2 diabetes: the trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants flow trial semaglutide kidney outcomes

The pressure created by the compression garment prevents fluid buildup and reduces swelling

By month 4, over 85% of patients on either medication report minimal ongoing symptoms

Researchers are investigating the peptides impact on melanin levels to understand its potential role in managing solar urticaria

The Food and Drug Administration (FDA) has not approved BPC-157or the vast majority of lifestyle peptidesfor human use in any capacity

PepsiCo CEO Ramon Laguarta mentioned the GLP-1 trend at the company's earnings announcement in February, saying he would expand smaller-portion products and pursue the development of products fortified with protein and dietary fiber